Pathos AI joins Bristol Myers and Tempus to build AI tools for Alzheimer’s drug development

Pathos AI is bringing patient records, AI analysis and pharmaceutical development expertise into a collaboration aimed at Alzheimer’s disease and other neurological conditions. Announced October 23, 2026, the agreements with Tempus AI and Bristol Myers Squibb pair a planned large-scale dataset with tools intended to guide research and clinical-trial design—not a newly developed treatment.

A five-year agreement for patient data

Tempus will build a de-identified dataset covering hundreds of thousands of patients with neurological conditions. It is designed to follow patient outcomes over time, rather than provide only a single snapshot of disease. Pathos will license that dataset through a five-year, $55 million agreement.

The dataset is still to be created. Tempus plans to use infrastructure and expertise it developed in oncology—the study and treatment of cancer—to assemble this neurological resource. Its assigned role is to supply curated patient information that can support research into disease biology and progression.

That establishes a specific division of work: Tempus builds the data resource; Pathos applies its Foundry AI platform; Bristol Myers contributes neuroscience drug-development expertise. The companies describe those pieces as complementary. The collaboration’s starting point is understanding neurological disease and using that understanding to advance potential therapies.

Neurological diseases demand more than any one company can bring on its own: the best longitudinal data, AI that can reason over it at scale, and the drug development expertise to turn insight into medicines.

Iker Huerga, CEO of Pathos AI

From disease hypotheses to trial decisions

Pathos says Foundry will analyze the dataset at scale, generate and test hypotheses about disease biology, and inform more targeted, adaptive clinical trials. Those are linked but distinct tasks: investigating how a disease works, then using the findings to help decide how a potential treatment should be studied.

Bristol Myers’s stated goals make the intended clinical use more concrete. It wants deeper insight into disease progression, help identifying patients most likely to benefit from potential therapies, and more precise trial designs. The emphasis is on decisions within drug development, rather than an AI service giving treatment advice directly to patients.

Pathos says it built and validated this approach in oncology, where Foundry helps guide its own clinical-stage drug pipeline. The company describes adapting trial designs in real time to improve their projected probability of success. That is a company claim about its existing approach—not a demonstrated improvement in neurological treatment outcomes from the new collaboration.

Exclusive in neuroscience, non-exclusive elsewhere

Bristol Myers will receive three-year exclusive rights to use Foundry for its neuroscience development programs. Across its broader portfolio, its strategic access to the platform will be non-exclusive. The announcement therefore gives the drugmaker different access terms depending on the area of research, rather than blanket exclusivity over Foundry.

The data license and platform rights also run on different clocks. Pathos’s agreement to license the Tempus dataset lasts five years; Bristol Myers’s neuroscience exclusivity lasts three. These are separate commitments within the collaboration: one secures the information Pathos intends to analyze, while the other defines a partner’s rights to use the AI platform.